One To Watch
Click Therapeutics
Company Overview
A biotechnology company that develops and commercializes prescription digital therapeutics using neuroscience-based software to treat neurological and psychiatric conditions. Click Therapeutics combines neuroscience with software engineering to create FDA-regulated prescription medical treatments delivered through mobile applications. The company focuses on addressing unmet medical needs in brain disorders through clinically-validated digital interventions. Click coined the term "Digital Therapeutics" to define this new modality of medicine.
Headquarters and Global Presence
Click Therapeutics is headquartered in New York City, New York. The company operates primarily in the United States market with a focus on FDA-regulated prescription digital therapeutics development and commercialization.
Founding and History
Click Therapeutics was founded in 2012 by David Benshoof Klein and Wei Kiddy Zhou. The company has raised $130 million in funding through multiple financing rounds, including a Series D round announced with Boehringer Ingelberg following FDA authorization of its lead programs. Click has achieved significant regulatory milestones with FDA authorization of digital therapeutics for episodic migraine and major depressive disorder.
Therapy Areas and Focus
Click Therapeutics focuses on neurological and psychiatric disorders, including migraine, major depressive disorder, and schizophrenia. The company collaborates across diverse therapeutic areas including psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. Click targets conditions where traditional pharmacological approaches have limitations or where digital interventions can provide complementary therapeutic benefits.
Technology Platforms and Modalities
Click's platform combines neuroscience research with software development to create prescription digital therapeutics delivered through mobile applications. The technology leverages cognitive behavioral interventions, neuroplasticity principles, and data analytics to deliver personalized therapeutic experiences. The platform generates real-world evidence through continuous patient monitoring and engagement tracking, enabling iterative optimization of therapeutic interventions.
Key Pipeline and Programs
CT-132 for episodic migraine has received FDA authorization and represents Click's lead commercial program. Rejoyn for major depressive disorder, co-developed with Otsuka Pharmaceuticals, has also achieved FDA authorization. CT-155 for schizophrenia is in development through a strategic partnership with Boehringer Ingelberg, supported by the recent Series D financing. The company maintains additional programs across multiple neuropsychiatric indications in various stages of clinical development.
Key Personnel
David B. Klein serves as Chief Executive Officer and co-founder, having coined the term "Digital Therapeutics" and led the company's strategic vision. Han Chiu holds the position of Chief Technology Officer, overseeing the company's software development and technical platforms. Austin C. Speier serves as Chief Strategy Officer, managing partnerships and commercial strategy.
Strategic Partnerships
Click maintains a strategic partnership with Otsuka Pharmaceuticals for the co-development of Rejoyn in major depressive disorder. The company has established a strategic partnership and received Series D investment from Boehringer Ingelberg for schizophrenia programs. Click previously secured Series C financing from Medidata and Dassault Systèmes, reflecting its focus on integrating digital therapeutics with pharmaceutical development infrastructure.
FAQ Section
Click must demonstrate that prescription digital therapeutics can achieve meaningful clinical outcomes comparable to traditional pharmaceuticals while establishing sustainable reimbursement and adoption pathways. The company faces the challenge of educating healthcare providers and payers about this new treatment modality.
Neurological and psychiatric conditions often involve behavioral and cognitive components that can be addressed through digital interventions targeting neuroplasticity. Many of these disorders have limited treatment options or significant side effects from traditional medications, creating opportunities for software-based therapeutic approaches.
Click combines rigorous neuroscience research with software engineering to create FDA-regulated prescription digital therapeutics rather than wellness apps. The company focuses on generating clinical evidence through controlled trials and maintains partnerships with established pharmaceutical companies to leverage existing commercialization infrastructure.
CT-132 represents one of the first FDA-authorized prescription digital therapeutics for migraine, validating the regulatory pathway for software-based treatments. The program demonstrates Click's ability to achieve regulatory approval and provides a foundation for commercial revenue generation in a large patient population.
Click's pipeline focuses primarily on neurological and psychiatric disorders including migraine, major depressive disorder, and schizophrenia. The company also collaborates in oncology, immunology, and cardiometabolic diseases where digital interventions can complement traditional pharmaceutical treatments.
Click is in early commercialization stage with two FDA-authorized programs (CT-132 and Rejoyn) and additional programs in clinical development. The company is transitioning from pure development to revenue generation while expanding its pipeline through strategic pharmaceutical partnerships.
Key factors to monitor include:
• Commercial adoption and reimbursement success for FDA-authorized programs CT-132 and Rejoyn
• Clinical development progress of CT-155 in schizophrenia with Boehringer Ingelberg partnership
• Expansion of pharmaceutical collaborations and pipeline diversification
• Regulatory precedents for digital therapeutics affecting market acceptance and competitive positioning
Latest Click Therapeutics News
Today's issue
| Headless Content Management with Blaze